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Key points  
• This article investigates the views of community pharmacists in Wales regarding 
spontaneous reporting of ADRs through the UK’s ‘Yellow Card Scheme’ 
• Key barriers to reporting identified by pharmacists were that they don’t see many 
ADRs, they don’t have time to report and there is difficulty identifying the causative 
drug 
• Main suggestions to increase reporting were being able to report through normal 
dispensing software, to have clearer guidance, and to receive remuneration for 
reporting  
• Pharmacists who had never reported an ADR were less confident about identifying 
and reporting ADRs and would particularly benefit from further guidance 
• Addressing community pharmacists’ self-identified barriers and facilitators may help 
increase reporting rates 
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Abstract  
 
Purpose: The UK’s ‘Yellow Card Scheme’ for reporting of adverse drug reactions (ADRs) has 
been operating for 50 years, but reporting rates by community pharmacists remain low. The 
aim of the study was therefore to investigate the views and experiences of ADR reporting by 
community pharmacists in Wales, with a particular focus on the potential barriers and 
facilitators to reporting. 
 
Methods: Following Ethics approval and piloting, a self-complete questionnaire was mailed to 
all registered community pharmacies in Wales, UK (n=713). A follow-up mailing was sent to 
non-responders after two weeks. 
 
Results: A response rate of 52% (n=372) was achieved, of whom 57% had never submitted a 
yellow card. Key barriers to reporting were not seeing ADRs, difficulty identifying the causative 
drug, not being sure which ADRs to report and lack of time. Key facilitators were being able to 
report through dispensary software and having clearer guidelines about what to report. 
Differences between those who had previously reported ADRs and those who had not 
suggested lack of confidence and uncertainty about what to report were more of a barrier for 
non-reporters. Conversely, reporters wanted feedback on reports, ability to keep reports on 
their dispensary records and remuneration to aid them with reporting. 
 
Conclusions: While the respondents generally expressed positive attitudes towards ADR 
reporting, a number of barriers and potential facilitators were nevertheless identified. Clearer 
support and guidance for reporting, such as through a ‘champions’ scheme similar to that run 
in Welsh hospitals may help current non-reporters to engage.  
 
 
 
 
  
Introduction 
 
Adverse drug reactions (ADRs) are of huge significance to healthcare in terms of the burden 
to individuals’ health and wellbeing, as well as the costs associated with treating patients with 
ADRs 1. In order to identify (and ideally therefore prevent) such ADRs, pharmacovigilance 
systems have been set up in many countries 2. These predominantly utilise spontaneous 
reports from health professionals and, increasingly, patients to monitor the safety of drugs 
throughout their marketed life. 
 
It is 50 years since the ‘Yellow Card Scheme’ (YCS) for spontaneous reporting of ADRs was 
launched in the United Kingdom 3. In the intervening years, a range of initiatives, including 
widening access, have been implemented to increase reporting rates, including allowing 
community pharmacists to join the scheme in 1999 3.  Nevertheless, in common with many 
other spontaneous reporting schemes, under-reporting (including by community pharmacists) 
is a limitation 4.  
 
The reasons for low reporting rates by community pharmacists are not easy to identify. 
Research which has looked into this issue is predominantly from countries where ADR 
spontaneous reporting schemes are relatively newly established such as India, Iran, Nepal, 
Nigeria and Saudi Arabia 5-13. The authors of these studies have identified possible reasons 
for non-reporting of ADRs such as lack of knowledge of the reporting schemes and processes, 
lack of awareness of the scheme, lack of access to reporting forms, lack of certainty regarding 
causality, reactions which are seen are too mild to report, reactions too well known to report 
and workload and time pressures 5-13. These findings may, however, be associated with the 
relative newness of the schemes – particularly lack of knowledge of how it works or access to 
forms. Nevertheless even in countries with more established schemes where pharmacists 
have been involved for longer, a number of barriers have been noted such as uncertainty 
regarding causation 14-15, lack of time 14-16, reactions which are seen are minor 15, reactions 
which are seen are well-known 14,16 and simply forgetting to report 15.  
 
In the UK, published studies which investigated community pharmacists’ role in ADR reporting 
were undertaken at the time when ADR reporting by community pharmacists was a pilot 
scheme (in the late 1990s) 17,18,19. Reasons for not reporting were identified as being the fact 
the reaction was well recognised 17,19, there was not enough information about the ADR 17, 
they were not sure about causality 19 and there was insufficient time in the working day for 
reporting 17. As considerable time has now passed and reporting by pharmacists has become 
established, reporting rates might be expected to have increased and indeed reporting rates 
by pharmacists in general have increased 20. Nevertheless, overall reporting by community 
pharmacists, particularly within Wales, is still relatively low 21-24; for example, just 4% of reports 
in Wales came from community pharmacists in 2013-14 21. Although initiatives such as linking 
ADR reporting to the New Medicine Service in England have boosted community pharmacist 
rates locally – such as a 92% increase in 2011-2 in the Northern and Yorkshire region 25, the 
levels still remain lower than for hospital pharmacists and doctors. It is important therefore to 
find out what is preventing community pharmacists from reporting. 
 
The aim of the study was therefore to investigate the views and experiences of ADR 
reporting by community pharmacists in Wales, with a particular focus on the potential 
barriers and facilitators to reporting. 
 
 
 
 
 
Methods 
 
Attitudes and experiences of community pharmacists working in Wales towards ADR reporting 
were assessed through means of a cross-sectional postal survey. Approval was granted from 
a University Ethics Committee to undertake the study. 
 
The questionnaire was developed based on the literature and exploratory interviews with a 
purposive sample of seven community pharmacists covering a range of roles and levels of 
experience including experience of the YCS. The questions included pharmacist 
demographics and experience of training on ADRs and reporting through the yellow card 
scheme. A further section asked about barriers and facilitators to reporting, while the final 
section provided a number of statements with which respondents were asked to indicate their 
level of agreement using a 5-point Likert-style scale ranging from strongly agree to strongly 
disagree. Questions were predominantly closed-format, although space was provided to 
expand on some answers (see appended questionnaire). There was opportunity at the end of 
the questionnaire for respondents to add any further comments on the topic. 
 
Following piloting on a random sample of 140 pharmacies in a demographically similar region 
in the North East of England, a few changes were made to the questionnaire. Most were 
related to formatting, but some additional questions were added relating to additional roles 
and qualifications and also respondents were asked to identify their main barrier / facilitator (if 
they had one). 
 
The amended questionnaire was mailed to all registered community pharmacies in Wales 
(n=713) addressed to ‘The Pharmacist’. This was for reasons of practicality and also ensured 
that those sent a questionnaire were actively working in community pharmacy. The addresses 
were obtained from the NHS Direct Wales website 26. Each questionnaire was coded to allow 
identification of non-responders and to determine the region in which the pharmacy was 
based. The mailing pack also contained a cover letter and freepost envelope. Respondents 
were asked to return the completed questionnaires within two weeks. After two weeks, non-
responders were identified and a repeat mailing sent. 
 
Data were analysed in SPSS® version 20 using descriptive statistics and comparative analysis 
between reporters and non-reporters through the YCS, using Fisher’s exact test. Qualitative 
data was coded and analysed using content analysis or thematic analysis as appropriate. 
 
Results 
 
A total of 372 questionnaires were returned; a response rate of 52%. There were equivalent 
proportions of male and female pharmacists (49.5% vs 50.4%) – other key demographics are 
shown in Table 1. In terms of experience of ADR reporting, 57% (208/368) of respondents had 
never reported an ADR through the YCS.  
 
Pharmacists were presented with a list of possible factors which may deter or prevent people 
from reporting ADRs. They were asked to tick all of those with which they agreed (four people 
did not answer this question). Respondents were then asked if they had one main barrier and, 
if so, to note which it was: 102 respondents stated a main barrier (one stated more than one 
option). The results are shown in Table 2.  Non-reporters were more likely to identify lack of 
confidence, uncertainty over what to report and not seeing ADRs as being barriers than were 
those who had previously reported an ADR (p=0.001, p=0.012, p<0.0005, respectively, 
Fisher’s exact test). 
 
Pharmacists were then given a list of possible factors which may encourage people to report 
ADRs. They were asked to tick all of those with which they agreed (fifteen people did not 
answer this question). Respondents were then asked if they had one main facilitator and, if 
so, to note which it was: 120 respondents stated a main facilitator (four stated more than one 
option). The results are shown in Table 3.  Non-reporters were more likely than reporters to 
identify clearer guidance as a facilitator (65% vs 52%, p=0.007 Fisher’s Exact) while reporters 
were more likely to identify getting feedback from the MHRA, being able to keep records of 
ADR reports in their dispensing software and remuneration as facilitators than did non-
reporters (Table 3). Non-reporters were also more likely than reporters to state that nothing 
would encourage them to report (5% vs 1%, p=0.030). 
 
In the final section of the questionnaire, a series of statements based on the literature or on 
the interviews were presented to the pharmacists who were asked to express their level of 
agreement with each statement. These related to a wide range of aspects of ADRs and ADR 
reporting. The respondents indicated positive attitudes towards reporting with the majority 
disagreeing with the statement that “ADR reporting is not my responsibility” (45% disagreed 
and 44% strongly disagreed). Similarly, the majority agreed that “I see ADR reporting as part 
of my professional role” (23% strongly agreed and 65% agreed). There were also positive 
attitudes towards patient reporting of ADRs with 11% strongly agreeing and 53% agreeing that 
they would be happy to encourage a patient to report through the YCS. Statements relating to 
identification of ADRs and reporting of ADRs are presented in Tables 4 and 5. 
 
Although the reporters’ overall view of the scheme was not significantly different from that of 
non-reporters, some differences were noted between reporters and non-reporters for certain 
statements. These differences are presented in Table 6.  
 
Discussion 
 
This study sought to obtain the views of community pharmacists working in Wales regarding 
ADR reporting. In general it was found that these pharmacists had positive views about ADR 
reporting, although fewer than half had ever submitted a report. Of the main barriers to 
reporting which were highlighted, a number were those previously identified in studies in other 
countries with established schemes 14-16, suggesting that community pharmacists in the UK 
are no different in terms of these universal issues such as time pressures and difficulties in 
identifying causative drugs. Similarly, harder to modify factors such as not seeing reportable 
reactions 14-16 were also identified in the present study. 
 
What was a more surprising finding in the current study was the lack of confidence in 
identifying and knowing how to report ADRs. This lack of certainty was also reflected in the 
proposed facilitators where respondents said they needed clearer guidance about what to 
report. While these factors have previously been reported in countries with newer reporting 
schemes 5-13, UK community pharmacists have been involved in ADR reporting for almost 20 
years. Further, during the pilot of community pharmacist ADR reporting only 3% said they 
lacked confidence to report 17. Since many of these pilot pharmacists received training as part 
of their participation, this may account for their confidence; likewise a study in Norway 27 found 
that training pharmacists helped address some of these factors. Since the issues around 
knowledge and confidence were particularly highlighted by those respondents who had never 
reported an ADR it may be these individuals would most benefit from some targeted training. 
Although, what is not clear is the relationship between these factors – are confident 
pharmacists more likely to report or do they become confident because they have had the 
experience of reporting? Further research into this association would be beneficial.  
 
While other research has identified barriers to reporting, there has been little consideration of 
what the potential reporters themselves think would increase their ability and willingness to 
report. The present study was able to identify a number of such facilitators which could 
increase reporting rates. The MHRA have already identified that many health professionals 
are unaware of the scheme 28 and while the respondents were generally aware of the scheme 
they still felt they needed more information about what they should be reporting - this could be 
addressed through promotional activities and alerts. Reminders and alerts appear to be 
beneficial in terms of acting as a prompt to increase reporting rates but the effects wear off 
over time 29. Therefore if these were to be utilised, as suggested by respondents, they would 
need to be appropriately timed to avoid reminder-fatigue. Peer support can also be a facilitator 
– the ‘Yellow Card Champions’ initiative launched in Wales in 2013 uses local hospital 
pharmacist ‘champions’ to promote ADR reporting in their workplace and support colleagues 
in reporting and has been associated with a rise in hospital pharmacist reporting 21. The 
scheme was extended to community-based pharmacists in 2016 30 and it is hoped that this 
will have a similar impact in due course. 
 
In terms of technology, a smart-phone ADR reporting application was launched by the MHRA 
in 2015 31, but this idea was not particularly popular with the study respondents as a facilitator. 
Rather, they preferred a system which would enable the pre-population of yellow card report 
forms from dispensary software. The use of such systems linkage between GP software and 
ADR reporting software has already resulted in significant increases in the numbers of GP 
reports submitted in England 20 and a similar approach could likewise enhance community 
pharmacist reporting, as suggested by the authors of a review paper in 2005 32. 
 
One facilitator which was particularly highlighted by those with experience of reporting was 
remuneration. This may reflect their views of the time and work involved in reporting, in 
contrast to those without such experience. This was also highlighted during the pilot phase of 
community pharmacist ADR reporting in the late 1990s, with 37% of respondents believing a 
fee would increase reporting rates 17. A small number of studies have looked at the role of 
small financial incentives for reporting and found this did lead to an increase in report numbers 
33,34 but it is not clear whether the costs are warranted for the benefits or whether the same (or 
greater) benefits can be achieved through other means. As such, this is unlikely to be taken 
up as a realistic facilitator by MHRA. 
 
Although the response rate for this study was only 52%, this is not unusual for similar surveys 
of pharmacists regarding ADRs 6,8,14. Importantly the sample included pharmacists actively 
working in community practice and therefore in a position to have opportunity to identify and 
report ADRs. A wide mix of demographics was also clear, suggesting a broad range of 
viewpoints could be obtained. Although a higher than expected proportion of respondents had 
reported an ADR, even these engaged participants were able to identify barriers and potential 
facilitators which may help to further enhance reporting rates.  
 
It is clear that, despite low reporting rates, community pharmacists demonstrate positive views 
about the importance of ADR reporting and are not averse to submitting reports with the right 
support in place. It is therefore hoped that more can be done to provide this support, such as 
provision of further training, alerts, peer support and innovative technology approaches. Such 
provisions can enable these willing pharmacists to become more active reporters, with 
subsequent benefits for patient safety. 
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Tables and figures  
 
Table 1 Respondent demographics N=372 
 Number % 
Number of company/ies worked for (6 did not answer) 
One 327 89 
More than one 39 11 
Type of company/ies worked for (4 did not answer) 
Large multinational 207 56 
Medium chain 54 15 
Small chain 48 13 
Independent 79 22 
Work hours (2 did not answer) 
Full time 300 81 
Part time 70 19 
Time since qualification (2 did not answer) 
0-2 years 32 9 
3-5 years 52 14 
6-10 years 59 16 
11-20 years 65 18 
21-30 years 76 21 
31-40 years 57 15 
Over 40 years 29 8 
Role (2 did not answer; 5 gave multiple answers) 
Locum pharmacist 15 4 
Relief pharmacist 18 5 
Manager 227 62 
Regular pharmacist 87 24 
Owner / proprietor 18 5 
Prescriber status (2 did not answer) 
Independent prescriber 4 1 
Supplementary prescriber 2 0.5 
None 364 98 
 
 
 
  
Table 2 Barriers to reporting (respondents could select more than one barrier then were asked to identify if 
they had a single main barrier) 
Possible barrier Agree 
(n=368) 
Identified as 
the main 
barrier 
(n=102) 
Significant differences between 
non-reporters (NR) and reporters 
(R) (Fisher’s exact test) 
NR R p-value 
I don’t see many ADRs 194 (53%) 25 (25%) - - - 
I don’t see many ADRs which 
meet the reporting criteria 
133 (36%) 9 (9%) 43% 26% <0.0005 
It’s often too difficult to 
identify the causative drug
  
113 (31%) 13 (13%) - - - 
I am not sure which ones I am 
supposed to report 
101 (27%) 10 (10%) 32% 21% 0.012 
I don’t have the time 76 (21%) 19 (19%) - - - 
Nothing deters or prevents me 
from reporting 
65 (18%) 2 (2%) - - - 
I’m not confident in identifying 
ADRs 
55 (15%) 5 (5%) 20% 8% 0.001 
I just don’t remember about 
the Yellow Card scheme 
44 (12%) 5 (5%) - - - 
I assume the patient’s GP will 
complete a Yellow Card 
instead  
44 (12%) 1 (1%) - - - 
I’d be worried I would have to 
complete ‘follow up’ reports 
which would generate a lot of 
work 
41 (11%) 2 (2%) - - - 
I don’t have access to the 
information I would need in 
order to report 
29 (8%) 4 (4%) - - - 
It’s too complicated to report 
  
17 (5%) - - - - 
I don’t see ADR reporting as a 
priority 
10 (3%) - - - - 
 
 
  
Table 3 Facilitators for reporting (respondents could select more than one facilitator then were asked to 
identify if they had a single main facilitator) 
Possible facilitator 
 
Agree 
(n=357) 
Identified as 
the main 
facilitator 
(n=120) 
Significant differences between 
non-reporters (NR) and reporters 
(R) (Fisher’s exact test) 
NR R p-value 
If I had a way of reporting 
through my normal dispensary 
software 
229 (64%) 41 (34%) - - - 
If there was clearer guidance 
about which reactions to 
report 
213 (60%) 41 (34%) 65% 52% 0.007 
If I were remunerated for 
reporting 
 
96 (27%) 15 (13%) 22% 33% 0.022 
If I received regular alerts to 
remind me about reporting 
81 (23%) 3 (3%) - - - 
If I knew I would get feedback 
from the MHRA with an 
update after submitting a 
report  
78 (22%) 3 (3%) 18% 28% 0.018 
If I had a way of keeping 
records of the ADRs I reported 
within my own dispensing 
software 
73 (20%) 2 (2%) 15% 28% 0.002 
If the Yellow Cards were more 
accessible 
57 (16%) 2 (2%) - - - 
If I had a reporting app for my 
smartphone 
56 (16%) 2 (2%) - - - 
If I received promotions about 
reporting through the post 
30 (8%) 2 (2%) - - - 
If there was a reminder about 
reporting on the front of the 
BNF 
30 (8%) 1 (0.8%) - - - 
Nothing would encourage me 
to report 
10 (3%) 2 (2%) - - - 
 
 
  
Table 4 Statements related to identification of ADRs: data presented as number of responses 
 
 
  
Statement Strongly 
Agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
Disagree 
Don’t 
know 
The Discharge Medicines 
Review is a good way to 
identify ADRs (n=369) 
44 185 93 28 10 9 
The Medicines Use 
Review service is a good 
opportunity to identify 
ADRs (n=369) 
104 237 23 2 2 1 
Patients are more likely 
to report ADRs to the 
pharmacist than to the 
GP (n=370) 
26 107 142 73 11 11 
Table 5 Statements relating to reporting of ADRs (barriers and facilitators): data presented as number of 
responses 
 
 
Statement Strongly 
Agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
Disagree 
Don’t 
know 
I have limited time and so 
other tasks take priority 
over ADR reporting 
(n=369) 
69 130 94 56 20 0 
Pharmacists should be 
remunerated for 
reporting ADRs (n=369) 
54 108 110 74 14 9 
With serious ADRs I 
usually refer the patient 
to the doctor and it’s up 
to them whether or not 
to complete a report 
(n=366) 
36 124 81 92 24 9 
I can’t easily access the 
Yellow Card website in 
work (n=369) 
40 80 77 98 38 36 
ADR reporting is 
promoted well (n=369) 
6 30 107 189 35 2 
I would be put off from 
reporting again if the 
MHRA did not 
acknowledge my report 
(n=369) 
20 115 122 87 20 5 
I would be worried about 
reporting in case I got it 
wrong (n=369) 
12 98 81 139 39 0 
I am confident in knowing 
which ADRs to report 
(n=370) 
11 107 106 122 20 4 
Table 6 Differences in responses to statements about ADR reporting between previous reporters and previous 
non-reporters of ADRs (data presented as %) 
	 Strongly 
Agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
Disagree 
Don’t 
know 
 
ADR reporting is not my responsibility*	
Reporters (n=159) 
 
0 0.6 3.1 49.7 48.4 0 
Non-reporters (n=205) 0 2.4 12.7 43.9 40.5 0.5 
 
I would be worried about reporting in case I got it wrong**	
Reporters (n=159) 
 
1.9 18.2 22.6 42.1 15.1 0 
Non-reporters (n=206) 4.4 32.5 20.9 35.0 7.3 0 
 
With serious ADRs I usually refer the patient to the doctor and it’s up to them whether or not to complete 
a report*	
Reporters (n=157) 7.6 26.8 21.7 30.6 10.2 3.2 
Non-reporters (n=205) 11.7 39.5 22.4 20.5 3.9 2.0 
 
I can’t easily access the Yellow Card website in work**	
Reporters (n=159) 
 
8.2 21.4 18.2 31.4 15.1 5.7 
Non-reporters (n=206) 13.1 21.8 22.8 22.3 6.8 13.1 
 
I see ADR reporting as part of my professional role*	
Reporters (n=159) 
 
26.4 68.6 3.8 1.3 0 0 
Non-reporters (n=207) 20.8 62.3 14.0 1.9 0.5 0.5 
 
Pharmacists should be remunerated for reporting ADRs*	
Reporters (n=158) 
 
12.0 34.8 29.1 20.3 0.6 3.2 
Non-reporters (n=207) 16.4 25.1 30.4 20.3 5.8 1.9 
 
I would be happy to encourage a patient to report through the Yellow Card Scheme*	
Reporters (n=159) 
 
13.8 57.9 10.1 15.1 1.3 1.9 
Non-reporters (n=206) 8.3 50.0 22.3 16.0 1.5 1.9 
 
I am confident knowing which ADRs to report**	
Reporters (n=159) 
 
5.0 37.1 29.6 23.3 3.1 1.9 
* p≤0.05, ** p≤0.005: Fisher’s exact, 2-sided significance 
 
 
Non-reporters (n=207) 1.4 22.2 28.0 40.6 7.2 0.5 
 
Adverse Drug Reaction Reporting 
Questionnaire 
 
 
 
The aim of this study is to find out the views and experiences of community 
pharmacists, like you, with regard to adverse drug reaction (ADR) reporting and 
the MHRA’s Yellow Card Scheme. 
 
 
It doesn’t matter if you have not reported an ADR: your views are really 
important to this research, regardless of whether or not you have made a report 
through the Yellow Card Scheme. 
 
 
The questionnaire should take no more than 10 minutes to complete. 
 
 
A freepost envelope is provided for you to return your questionnaire. 
 
 
Please remember that all replies are completely confidential. 
 
 
 
 
 
Instructions: 
Please just tick one answer for each question unless instructed otherwise. 
 
Please note that the abbreviation ‘ADR’ for ‘adverse drug reaction’ is used throughout this 
questionnaire. ‘Adverse drug reaction’ is being used to cover all drug-induced effects from 
minor side effects to serious reactions. 
 
A) Background Questions  
 
In order to help analyse the data, please answer the following questions about yourself: 
 
A1) Are you:   Male   Female 
 
A2) Approximately how long have you been qualified as a pharmacist? 
 
0-2 years  3-5 years     6-10 years         11-20 years  
21-30 years  31-40 years   Over 40 years 
 
A3) Are you qualified as a supplementary or independent prescriber? 
   
 No  Yes, supplementary  prescriber  Yes, independent prescriber 
 
A4a) Do you work for more than one pharmacy company?     Yes  No 
 
A4b) How would you describe this company(ies)? (Please tick all which apply) 
 
Large Multinational    Medium sized chain (over 10 pharmacies) 
Small chain (up to 10 pharmacies) Independent pharmacy 
 
A5) How would you describe your position? 
 
Locum   Relief pharmacist    Manager  Regular pharmacist 
 
Other (please state)           
 
A6) Do you work full time or part time as a community pharmacist? 
 
Full time (more than 35 hours per week)  Part time (35 hours or less per week) 
 
A7) Do you work as a pharmacist in any other settings? (Please tick all which apply) 
 
Industry  Primary care  Hospital  Academia 
Other e.g. portfolio / interface (please state) ________________________________ 
 
B) ADR Education and Training 
 
B1) Have you received any education or training about identifying and/or reporting ADRs? 
 
No, I have not received any training or education on ADRs (go to section C) 
Yes, but only as an undergraduate (go to section C) 
Yes, but only post-qualification (go to question B2) 
Yes, both while an undergraduate and post-qualification (go to question B2) 
 B2a) If you have received post-qualification education or training on ADRs was this (please 
tick all which apply) 
Part of a postgraduate Diploma / Masters / other degree 
Provided through an education /training body (e.g. a course / distance learning pack) 
Informal CPD activity (e.g. reading journals) 
Other (please state)           
 
B2b) How long ago did you last receive education or training on ADRs? 
Within the     Over one year ago but  Longer than  
last year   within the last five years  five years ago 
 
C) ADR Experiences 
 
C1) While working as a community pharmacist, approximately how often do you see an ADR 
(either ones you have identified or ones the patients present with)? 
 More than once a day  Once a day 
 Once a week   Once a fortnight 
 Once a month  Less than once a month 
 Never   
 
C2a) In your day-to-day practice how would you distinguish a ‘serious’ ADR from a ‘minor’ 
ADR? 
 
 
 
 
 
 
C2b) Approximately what proportion of the ADRs you see would you class as ‘serious’? 
All  Most (≥ 50%)   Some (< 50%)  None 
 
C3) Have you ever reported an ADR through the Yellow Card scheme? 
Yes (go to question C4)  No (please go to section D, on the next page) 
 
C4)  How many yellow cards have you submitted during your career? 
 One  2-5  6-10  11-15   16-20  >20 
 
C5a) Considering the last report you submitted, how long ago was this? 
Within the last month More than one month ago but in the last year 
More than a year ago but in the  Longer than five years ago 
last five years   
 
C5b) How did you submit this report? 
Using a Yellow Card from the BNF, sent in the post 
Using a Yellow Card downloaded from the MHRA website, sent in the post 
Using a Yellow Card you obtained from elsewhere (please state where below) 
Online through the MHRA website 
Other (please state)           
 
C5c) What is the main reason you decided to report this reaction? 
 
  
 
 
 
C5d) How did you find the process of reporting? (Please tick all which apply) 
Easy   Complicated      Quick   
Difficult  Straightforward     Time-consuming 
 
Please use the box below to briefly explain your answer or add any additional comments. 
 
 
 
 
 
 
D) Views on ADR reporting 
 
D1a) What are the factors that deter or prevent you from reporting ADRs? (Please tick all 
which apply) 
D1b) Which of these is the main barrier for you? __________________________________ 
___________________________________ (Leave blank if no single main barrier) 
D2) What factors would encourage you to report ADRs? (Please tick all which apply) 
 I don’t have the time  I am not sure which ones I am 
supposed to report 
 I don’t see many ADRs  I don’t see many ADRs which meet the 
reporting criteria 
 I don’t see ADR reporting as a priority  It’s often too difficult to identify the 
causative drug  
 It’s too complicated to report    I assume the patient’s GP will 
complete a Yellow Card instead  
 I’m not confident in identifying ADRs  I just don’t remember about the Yellow 
Card scheme 
 I don’t have access to the information 
I would need in order to report 
 I’d be worried I would have to complete 
‘follow up’ reports which would 
generate a lot of work 
 Nothing deters or prevents me from 
reporting 
 Other (please state)   
      
      
 
D2b) Which of these would be the main factor to encourage you? ____________________ 
________________________________________ (Leave blank if no single main factor) 
 
D3) Which of the following do you feel have a responsibility to report ADRs? (Please tick all 
which apply) 
 
Doctor  Pharmacist  Nurse   Dentist  
Patient / Carer No-one  Other (please state) _________________ 
 
 
D4) What do you think of the current Yellow Card reporting scheme overall? 
It works very well as it is and no improvements are needed 
It works well but some improvements could be made 
It works fairly well but some improvements are needed 
It doesn’t work very well and improvements are needed 
 
 
If you feel improvements are needed, please use the box below to briefly explain what these 
are. 
 
 
 
  
 If the Yellow Cards were more 
accessible 
 If I had a way of reporting through my 
normal dispensary software 
 If there was a reminder about 
reporting on the front of the BNF 
 If I had a reporting app for my 
smartphone 
 If there was clearer guidance about 
which reactions to report 
 If I knew I would get feedback from the 
MHRA with an update after submitting 
a report  
 If I received promotions about 
reporting through the post 
 If I had a way of keeping records of the 
ADRs I reported within my own 
dispensing software 
 If I received regular alerts to remind 
me about reporting 
 If I were remunerated for reporting 
 
 Nothing would encourage me to 
report 
 Other (please state)   
      
      
D5) For EACH of the following statements, please indicate your level of agreement.  
 Statement Strongly 
Agree 
Agree Neither 
agree nor 
disagree 
Disagree Strongly 
Disagree 
Don’t 
know 
a I have limited time and so 
other tasks take priority 
over ADR reporting  
      
b ADR reporting is not my 
responsibility 
      
c The Discharge Medicines 
Review is a good way to 
identify ADRs 
      
d I see ADR reporting as 
part of my professional 
role 
      
e Patients are more likely 
to report ADRs to the 
pharmacist than to the 
GP 
      
f Pharmacists should be 
remunerated for reporting 
ADRs 
      
g With serious ADRs I 
usually refer the patient 
to the doctor and it’s up 
to them whether or not to 
complete a report 
      
h I can’t easily access the 
Yellow Card website in 
work 
      
i ADR reporting is 
promoted well 
      
j The MUR service is a 
good opportunity to 
identify ADRs 
      
k I would be put off from 
reporting again if the 
MHRA did not 
acknowledge my report 
      
l I would be worried about 
reporting in case I got it 
wrong 
      
m I would be happy to 
encourage a patient to 
report through the Yellow 
Card scheme 
      
n I am confident in knowing 
which ADRs to report 
      
E) Final comments 
 
Do you have any other comments about ADR reporting? If so, please use the box below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thanks for taking the time to complete this questionnaire 
 
 
 
 
Now please place it in the freepost envelope provided and return to:  
 
Pharmacy Education and Practice, FREEPOST CF3505, Cardiff School of Pharmacy and 
Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, 
Cardiff CF10 3NB 
 
